Facebook icon Twitter icon Forward icon

Insulin glargine and lixisenatide study results released

A combination of insulin glargine and lixisenatide helps people with type 2 diabetes reach meal-time blood sugar targets, according to a new study.

The LixiLan-L trial investigated a fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide (iGlarLixi) in adults with type 2 diabetes. To read more, click here

Study shows Xultophy boosts glycaemic targets

Adults with type 2 diabetes treated with Xultophy® (insulin degludec/liraglutide) are up to 4.5 times more likely to achieve glycaemic targets without hypoglycaemia and weight gain, research has suggested.

The Novo Nordisk trial compared two groups of type 2 diabetes patients uncontrolled on insulin glargine U100, treated with either insulin degludec/liraglutide or up-titrated insulin glargine U100. To read more, click here

Positive results from type 2 combination drug trial

The combination of a GLP-1 receptor agonist and a SGLT-2 inhibitor has shown positive results in those with type 2 diabetes who do not respond to metformin.

The DURATION-8 trial showed Bydureon® (exenatide once-weekly) 2mg once weekly in combination with Forxiga® (dapagliflozin) 10mg once daily significantly reduced HbA1c. To read more, click here

Liraglutide delays progression of renal events

The glucagonlike-peptide 2 (GLP-1) agonist liraglutide (Victoza) delays the progression of renal events, according to new research.

The findings, carried out by Novo Nordisk, found the drug particularly delayed the new-onset of persistent new- macroalbuminuria in people with type 2 diabetes. To read more, click here

Ninjabetic – The love of learning

As I sat back on my sofa with a cup of tea in my hand, feet up and my day-to-day tasks behind me, I realised what a beautiful thing online learning is.

It’s fast, fun, easy to access and it suits my life. There I was refreshing my memory on the carb counting skills I had learned four years ago (which are now very rusty, I have to say!), from the comfort of my own home, with the option to take as long as I needed or to skip to another section as and when I was ready. To read more, click here